Your session is about to expire
← Back to Search
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Ingrezza for Cervical Dystonia
Phase 4
Waitlist Available
Led By Martin Taylor, DO, PHD
Research Sponsored by The Orthopedic Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights
Study Summary
Study of Ingrezza (Valbenazine) for the treatment of cervical dystonia.
Eligible Conditions
- Cervical Dystonia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in incidence of pain/spasm
Trial Design
1Treatment groups
Experimental Treatment
Group I: IngrezzaExperimental Treatment1 Intervention
Participants will receive Ingrezza orally once daily for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ingrezza Pill
2021
Completed Phase 4
~20
Find a Location
Who is running the clinical trial?
The Orthopedic FoundationLead Sponsor
Martin Taylor, DO, PHDPrincipal Investigatorprinciple investigator
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
Illinois
South Carolina
Missouri
How old are they?
18 - 65
What site did they apply to?
The Orthopedic foundation
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Share this study with friends
Copy Link
Messenger